Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Oct;74(7):1132–1136. doi: 10.1038/bjc.1996.502

Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.

A H Honkoop 1, K Hoekman 1, J Wagstaff 1, C J van Groeningen 1, J B Vermorken 1, E Boven 1, H M Pinedo 1
PMCID: PMC2077104  PMID: 8855987

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a haematopoietic growth factor with a wide variety of applications in the clinic. In early phase I studies the continuous intravenous (c.i.) route of administration was often used. Later it was shown that subcutaneous (s.c.) administration was also effective. The optimal route of administration remains, however, poorly defined, and no studies have made a direct comparison between these two routes of administration. We treated patients with advanced breast cancer with moderately high-dose doxorubicin and cylophosphamide and GM-CSF. The first 14 patients received GM-CSF by c.i, while subsequently 47 patients received it s.c. Comparison between the two groups showed that c.i. GM-CSF was more toxic in several respects. There was a higher need for erythrocyte and platelet transfusions and a significant deterioration in the performance status. This study indicates that subcutaneous GM-CSF is the preferred route of administration. Randomised trials are, however, needed to confirm these conclusions.

Full text

PDF
1132

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antin J. H., Smith B. R., Holmes W., Rosenthal D. S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood. 1988 Aug;72(2):705–713. [PubMed] [Google Scholar]
  2. Antman K. S., Griffin J. D., Elias A., Socinski M. A., Ryan L., Cannistra S. A., Oette D., Whitley M., Frei E., 3rd, Schnipper L. E. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 8;319(10):593–598. doi: 10.1056/NEJM198809083191001. [DOI] [PubMed] [Google Scholar]
  3. Ardizzoni A., Venturini M., Sertoli M. R., Giannessi P. G., Brema F., Danova M., Testore F., Mariani G. L., Pennucci M. C., Queirolo P. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. Br J Cancer. 1994 Feb;69(2):385–391. doi: 10.1038/bjc.1994.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bishop M. R., Anderson J. R., Jackson J. D., Bierman P. J., Reed E. C., Vose J. M., Armitage J. O., Warkentin P. I., Kessinger A. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood. 1994 Jan 15;83(2):610–616. [PubMed] [Google Scholar]
  5. Brandt S. J., Peters W. P., Atwater S. K., Kurtzberg J., Borowitz M. J., Jones R. B., Shpall E. J., Bast R. C., Jr, Gilbert C. J., Oette D. H. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988 Apr 7;318(14):869–876. doi: 10.1056/NEJM198804073181401. [DOI] [PubMed] [Google Scholar]
  6. Cebon J., Dempsey P., Fox R., Kannourakis G., Bonnem E., Burgess A. W., Morstyn G. Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. Blood. 1988 Oct;72(4):1340–1347. [PubMed] [Google Scholar]
  7. Cebon J., Lieschke G. J., Bury R. W., Morstyn G. The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. Br J Haematol. 1992 Feb;80(2):144–150. doi: 10.1111/j.1365-2141.1992.tb08891.x. [DOI] [PubMed] [Google Scholar]
  8. Edmonson J. H., Long H. J., Jeffries J. A., Buckner J. C., Colon-Otero G., Fitch T. R. Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency. J Natl Cancer Inst. 1989 Oct 4;81(19):1510–1512. doi: 10.1093/jnci/81.19.1510-a. [DOI] [PubMed] [Google Scholar]
  9. Gerhartz H. H., Engelhard M., Meusers P., Brittinger G., Wilmanns W., Schlimok G., Mueller P., Huhn D., Musch R., Siegert W. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood. 1993 Oct 15;82(8):2329–2339. [PubMed] [Google Scholar]
  10. Gianni A. M., Siena S., Bregni M., Tarella C., Stern A. C., Pileri A., Bonadonna G. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet. 1989 Sep 9;2(8663):580–585. doi: 10.1016/s0140-6736(89)90711-3. [DOI] [PubMed] [Google Scholar]
  11. Gordon B., Spadinger A., Hodges E., Ruby E., Stanley R., Coccia P. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol. 1994 Sep;12(9):1917–1922. doi: 10.1200/JCO.1994.12.9.1917. [DOI] [PubMed] [Google Scholar]
  12. Groopman J. E., Mitsuyasu R. T., DeLeo M. J., Oette D. H., Golde D. W. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med. 1987 Sep 3;317(10):593–598. doi: 10.1056/NEJM198709033171003. [DOI] [PubMed] [Google Scholar]
  13. Harmenberg J., Höglund M., Hellström-Lindberg E. G- and GM-CSF in oncology and oncological haematology. Eur J Haematol Suppl. 1994;55:1–28. doi: 10.1111/j.1600-0609.1994.tb01617.x. [DOI] [PubMed] [Google Scholar]
  14. Hill R. J., Warren M. K., Levin J. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest. 1990 Apr;85(4):1242–1247. doi: 10.1172/JCI114559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hoekman K., Wagstaff J., van Groeningen C. J., Vermorken J. B., Boven E., Pinedo H. M. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst. 1991 Nov 6;83(21):1546–1553. doi: 10.1093/jnci/83.21.1546. [DOI] [PubMed] [Google Scholar]
  16. Hoekman K., von Blomberg-van der Flier B. M., Wagstaff J., Drexhage H. A., Pinedo H. M. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet. 1991 Aug 31;338(8766):541–542. doi: 10.1016/0140-6736(91)91103-2. [DOI] [PubMed] [Google Scholar]
  17. Kaplan L. D., Kahn J. O., Crowe S., Northfelt D., Neville P., Grossberg H., Abrams D. I., Tracey J., Mills J., Volberding P. A. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol. 1991 Jun;9(6):929–940. doi: 10.1200/JCO.1991.9.6.929. [DOI] [PubMed] [Google Scholar]
  18. Lieschke G. J., Maher D., Cebon J., O'Connor M., Green M., Sheridan W., Boyd A., Rallings M., Bonnem E., Metcalf D. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med. 1989 Mar 1;110(5):357–364. doi: 10.7326/0003-4819-110-5-357. [DOI] [PubMed] [Google Scholar]
  19. Lieschke G. J., Maher D., O'Connor M., Green M., Sheridan W., Rallings M., Bonnem E., Burgess A. W., McGrath K., Fox R. M. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res. 1990 Feb 1;50(3):606–614. [PubMed] [Google Scholar]
  20. Lockhart P. B., Sonis S. T. Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1979 Jul;48(1):21–28. doi: 10.1016/0030-4220(79)90230-5. [DOI] [PubMed] [Google Scholar]
  21. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nemunaitis J., Rabinowe S. N., Singer J. W., Bierman P. J., Vose J. M., Freedman A. S., Onetto N., Gillis S., Oette D., Gold M. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991 Jun 20;324(25):1773–1778. doi: 10.1056/NEJM199106203242504. [DOI] [PubMed] [Google Scholar]
  23. O'Shaughnessy J. A., Denicoff A. M., Venzon D. J., Danforth D., Pierce L. J., Frame J. N., Bastian A., Ghosh B., Goldspiel B., Miller L. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Ann Oncol. 1994 Oct;5(8):709–716. doi: 10.1093/oxfordjournals.annonc.a058975. [DOI] [PubMed] [Google Scholar]
  24. Ruef C., Coleman D. L. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis. 1990 Jan-Feb;12(1):41–62. doi: 10.1093/clinids/12.1.41. [DOI] [PubMed] [Google Scholar]
  25. Rusten L. S., Jacobsen S. E. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood. 1995 Feb 15;85(4):989–996. [PubMed] [Google Scholar]
  26. Sisson S. D., Dinarello C. A. Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood. 1988 Oct;72(4):1368–1374. [PubMed] [Google Scholar]
  27. Stehle B., Weiss C., Ho A. D., Hunstein W. Serum levels of tumor necrosis factor alpha in patients treated with granulocyte-macrophage colony-stimulating factor. Blood. 1990 May 1;75(9):1895–1896. [PubMed] [Google Scholar]
  28. Steward W. P., Scarffe J. H., Austin R., Bonnem E., Thatcher N., Morgenstern G., Crowther D. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. Br J Cancer. 1989 Jan;59(1):142–145. doi: 10.1038/bjc.1989.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Vadhan-Raj S., Buescher S., LeMaistre A., Keating M., Walters R., Ventura C., Hittelman W., Broxmeyer H. E., Gutterman J. U. Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1988 Jul;72(1):134–141. [PubMed] [Google Scholar]
  30. Vadhan-Raj S., Keating M., LeMaistre A., Hittelman W. N., McCredie K., Trujillo J. M., Broxmeyer H. E., Henney C., Gutterman J. U. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987 Dec 17;317(25):1545–1552. doi: 10.1056/NEJM198712173172501. [DOI] [PubMed] [Google Scholar]
  31. de Vries E. G., Willemse P. H., Biesma B., Stern A. C., Limburg P. C., Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet. 1991 Aug 24;338(8765):517–518. doi: 10.1016/0140-6736(91)90594-f. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES